- Home
- PSTL vs DMAC Comparison
PSTL vs DMAC Comparison
Compare PSTL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- DMAC
- Stock Information
- Founded
- PSTL 2018
- DMAC 2000
- Country
- PSTL United States
- DMAC United States
- Employees
- PSTL N/A
- DMAC N/A
- Industry
- PSTL Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- DMAC Health Care
- Exchange
- PSTL Nasdaq
- DMAC Nasdaq
- Market Cap
- PSTL 329.8M
- DMAC 310.1M
- IPO Year
- PSTL 2019
- DMAC N/A
- Fundamental
- Price
- PSTL $14.96
- DMAC $6.93
- Analyst Decision
- PSTL Buy
- DMAC Strong Buy
- Analyst Count
- PSTL 2
- DMAC 3
- Target Price
- PSTL $17.38
- DMAC $12.33
- AVG Volume (30 Days)
- PSTL 165.7K
- DMAC 367.9K
- Earning Date
- PSTL 11-03-2025
- DMAC 11-12-2025
- Dividend Yield
- PSTL 6.47%
- DMAC N/A
- EPS Growth
- PSTL 344.13
- DMAC N/A
- EPS
- PSTL 0.39
- DMAC N/A
- Revenue
- PSTL $86,535,000.00
- DMAC N/A
- Revenue This Year
- PSTL $23.20
- DMAC N/A
- Revenue Next Year
- PSTL $10.24
- DMAC N/A
- P/E Ratio
- PSTL $38.72
- DMAC N/A
- Revenue Growth
- PSTL 26.43
- DMAC N/A
- 52 Week Low
- PSTL $12.26
- DMAC $3.19
- 52 Week High
- PSTL $16.50
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- PSTL 31.89
- DMAC 59.52
- Support Level
- PSTL $15.27
- DMAC $6.66
- Resistance Level
- PSTL $15.71
- DMAC $7.10
- Average True Range (ATR)
- PSTL 0.29
- DMAC 0.30
- MACD
- PSTL -0.14
- DMAC -0.06
- Stochastic Oscillator
- PSTL 0.65
- DMAC 52.83
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.